Comments on new drug licence

Albert Saporta

CEO

Paris, June 25, 2008 — Stallergenes, a French biopharmaceutical company specialised in desensitisation treatments for allergy-related respiratory diseases , was just licenced to sell its new drug Oralair Grasses in Germany. Stallergenes CEO Albert Saporta comments on the news and on the outlook for his company.
– Company website: www.stallergenes.com